About Biodefense
Biodefense is the use of medical measures to protect people against bioterrorism. It mainly applies to two different target populations, namely military combatant (troops in the field) and civilian non-combatant. The protection of food supplies and water are often considered a critical part of biodefense. Owing to the increasing threat of terrorism and bioterrorism, the risk posed by exposure to biological agents that can be used as biological weapons must be evaluated. Biological agents used in warfare may prove to be more potent than conventional weapons. In the last century, the developments made in biochemistry and biotechnology have simplified the production of such weapons. Genetic engineering can be used to create new pathogens by manipulating genes, thereby giving rise to a whole new generation of genetically modified bioweapons. Factors such as ease of production, availability of technical know-how, and the extensive accessibility of biological agents have further led to the threat of biological weapons.
Technavio’s analysts forecast the global biodefense market to grow at a CAGR of 5.41% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global biodefense market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of biodefense.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Biodefense market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Altimmune
• Bavarian Nordic
• DynPort Vaccine Company (DVC)
• Emergent BioSolutions
Other prominent vendors
• Acambis
• Achaogen
• Cleveland BioLabs
• Elusys Therapeutics
Market driver
• Growing threat of bioterrorism
• For a full, detailed list, view our report
Market challenge
• Lack of information about bioengineered organisms attack
• For a full, detailed list, view our report
Market trend
• Government initiatives
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
PART 05: MARKET LANDSCAPE
• Market overview
PART 06: FIVE FORCES ANALYSIS
• Five forces analysis
PART 07: MARKET SEGMENTATION BY APPLICATION
• Comparison by application
• Global biodefense against anthrax market
• Global biodefense against smallpox market
• Global biodefense against botulism market
• Global biodefense against others market
• Market opportunity
PART 08: REGIONAL LANDSCAPE
• Regional comparison
• Biodefense market in Americas
• Biodefense market in EMEA
• Biodefense market in APAC
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Government initiatives
• Growing collaborations and M&A
PART 12: VENDOR LANDSCAPE
• Competitive landscape
• Altimmune
• Bavarian Nordic
• DynPort Vaccine Company (DVC)
• Emergent BioSolutions
• Other prominent vendors
PART 13: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: CDC classification of bioterrorism agents
Exhibit 02: Global biodefense market: Snapshot
Exhibit 03: Global biodefense market 2016-2021 ($ millions)
Exhibit 04: Global biodefense market: Year-over-year (YoY) growth 2017-2021 (%)
Exhibit 05: Global biodefense market: Opportunity analysis
Exhibit 06: Five forces analysis
Exhibit 07: Global biodefense market share by application 2016-2021 (%)
Exhibit 08: Comparison by application
Exhibit 09: Spread of anthrax
Exhibit 10: Types of anthrax
Exhibit 11: Global biodefense against anthrax market 2016-2021 ($ millions)
Exhibit 12: Global biodefense against anthrax market: YoY growth 2017-2021 (%)
Exhibit 13: Factors responsible for making anthrax a deadly bioweapon
Exhibit 14: Types of anthrax vaccine
Exhibit 15: Global biodefense against smallpox market 2016-2021 ($ millions)
Exhibit 16: Global biodefense against smallpox market: YoY growth 2017-2021 (%)
Exhibit 17: Types of botulism
Exhibit 18: Global biodefense against botulism market 2016-2021 ($ millions)
Exhibit 19: Global biodefense against botulism market: YoY growth 2017-2021 (%)
Exhibit 20: Global biodefense against others market 2016-2021 ($ millions)
Exhibit 21: Global biodefense against others market: YoY growth 2017-2021 (%)
Exhibit 22: Global biodefense market share by region 2016-2021 (%)
Exhibit 23: Regional comparison
Exhibit 24: Biodefense market in Americas 2016-2021 ($ millions)
Exhibit 25: Biodefense market: YoY growth in Americas (%)
Exhibit 26: Biodefense market in EMEA 2016-2021 ($ millions)
Exhibit 27: Biodefense market: YoY growth in EMEA 2017-2021 (%)
Exhibit 28: Biodefense market in APAC 2016-2021 ($ millions)
Exhibit 29: Biodefense market: YoY growth in APAC 2017-2021 (%)
Exhibit 30: Key leading countries
Exhibit 31: Recent outbreaks, 2017
Exhibit 32: Competitive structure analysis of global biodefense market
Exhibit 33: Altimmune: Key highlights
Exhibit 34: Altimmune: Strength assessment
Exhibit 35: Altimmune: Strategy assessment
Exhibit 36: Altimmune: Opportunity assessment
Exhibit 37: Bavarian Nordic: Key highlights
Exhibit 38: Bavarian Nordic: Strength assessment
Exhibit 39: Bavarian Nordic: Strategy assessment
Exhibit 40: Bavarian Nordic: Opportunity assessment
Exhibit 41: DVC: Key highlights
Exhibit 42: DVC: Strength assessment
Exhibit 43: DVC: Strategy assessment
Exhibit 44: DVC: Opportunity assessment
Exhibit 45: Emergent BioSolutions: Key highlights
Exhibit 46: Emergent BioSolutions: Strength assessment
Exhibit 47: Emergent BioSolutions: Strategy assessment
Exhibit 48: Emergent BioSolutions: Opportunity assessment
